UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2026
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”)
published one announcement (the “Public Notice”) to the Australian Securities Exchange on September 22, 2026 titled:
“Change of Director’s Interest Notices x 4”
A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.
This report on Form 6-K (including any exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated
by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by
specific reference in such registration statement or prospectus.
EXHIBITS
Exhibit
Number |
|
Description |
| 99.1 |
|
Change of Director’s Interest Notices x 4 |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
RADIOPHARM THERANOSTICS LIMITED |
| |
|
|
| Date: September 22, 2026 |
By: |
/s/ Amritha Sushil |
| |
|
Amritha Sushil |
| |
|
Company Secretary |
Exhibit 99.1
Appendix
3Y
Change
of Director’s Interest Notice
Rule
3.19A.2
Appendix
3Y
Change
of Director’s Interest Notice
Information
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property
and may be made public.
Introduced
30/9/2001. Amended 01/01/11
| Name
of Entity: |
Radiopharm
Theranostics Limited (ASX: RAD) |
| ABN: |
57
647 877 889 |
We
(the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section
205G of the Corporations Act.
| Name
of Director: |
Bruce
Goodwin |
| Date
of Last Notice: |
19
November 2025 |
Part
1 - Change of director’s relevant interests in securities
In
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note:
In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director”
should be disclosed in this part.
| Direct
or Indirect Interest |
Indirect |
|
| |
|
|
Nature
of indirect interest
(including
registered holder)
Note:
Provide details of the circumstances giving rise to the relevant interest. |
Sundial
Management Pty Limited of which Mr Goodwin is a Director and Shareholder. |
|
| |
|
|
| Date
of change |
17
September 2026 |
| |
|
| No.
of securities held prior to change |
Nil |
| |
|
| Class |
a.
Fully Paid Ordinary Shares |
| |
b. Listed
Options |
|
|
| Number
acquired |
a.
2,777,778 Fully Paid Ordinary Shares |
| |
b. 2,777,778
Listed Options, EXP 31 Jul 29, EX $0.018 |
| |
|
| Number
disposed |
Nil |
| |
|
|
|
|
|
Value/Consideration
Note:
If
consideration is non-cash, provide details and estimated valuation |
a.
$25,000 ($0.009 per Share)
b. Nil |
|
| + See chapter 19 for defined terms. | |
| | |
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix
3Y
Change
of Director’s Interest Notice
| No.
of securities held after change |
|
|
Shares |
Options |
|
| |
|
Indirect |
2,777,778 |
2,777,778 |
|
| |
|
|
Nature
of change
Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend
reinvestment plan, participation in buy-back |
Acquisition
of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September
2026. |
Part
2 – Change of director’s interests in contracts
Note:
In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director”
should be disclosed in this part.
| Detail
of contract |
N/A |
| Nature
of interest |
N/A |
Name
of registered holder
(if
issued securities) |
N/A |
| Date
of change |
N/A |
No.
and class of securities to which interest related prior to change
Note:
Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest
acquired |
N/A |
| Interest
disposed |
N/A |
Value/Consideration
Note:
If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest
after change |
N/A |
| + See chapter 19 for defined terms. | |
| | |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix
3Y
Change
of Director’s Interest Notice
Part
3 – Closed period
| Were
the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? |
No |
| If
so, was prior written clearance provided to allow the trade to proceed during this period? |
N/A |
| If
prior written clearance was provided, on what date was this provided? |
N/A |
| + See chapter 19 for defined terms. | |
| | |
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix
3Y
Change
of Director’s Interest Notice
Rule
3.19A.2
Appendix
3Y
Change
of Director’s Interest Notice
Information
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property
and may be made public.
Introduced
30/9/2001. Amended 01/01/11
| Name
of Entity: |
Radiopharm
Theranostics Limited (ASX: RAD) |
| ABN: |
57
647 877 889 |
We
(the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section
205G of the Corporations Act.
| Name
of Director: |
Ian
Turner |
| Date
of Last Notice: |
27
August 2026 |
Part
1 - Change of director’s relevant interests in securities
In
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note:
In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director”
should be disclosed in this part.
| Direct
or Indirect Interest |
Direct
and indirect |
|
| |
|
|
Nature
of indirect interest
(including
registered holder)
Note:
Provide details of the circumstances giving rise to the relevant interest. |
Superannuation
fund |
|
| |
|
|
| Date
of change |
17
September 2026 |
| |
|
|
|
|
|
| No.
of securities held prior to change |
|
|
Shares |
Options |
|
| |
|
Direct |
2,530,595 |
21,956,926 |
|
| |
|
Indirect |
7,454,697 |
70,422 |
|
| |
|
Total |
9,985,292 |
22,027,348 |
| |
|
|
|
|
|
| Class |
a. Fully
Paid Ordinary Shares |
|
| |
b. Listed
Options |
|
| |
|
|
| Number
acquired |
Direct |
|
| |
a. 1,222,222
Fully Paid Ordinary Shares |
|
| |
b. 1,222,222
Listed Options, EXP 31 Jul 29, EX $0.018 |
|
| |
|
|
| |
Indirect |
|
| |
a. 1,555,556
Fully Paid Ordinary Shares |
|
| |
b. 1,555,556
Listed Options, EXP 31 Jul 29, EX $0.018 |
|
| |
|
|
| Number
disposed |
Nil |
|
| |
|
|
|
|
|
Value/Consideration
Note:
If
consideration is non-cash, provide details and estimated valuation |
a. $25,000
($0.009 per Share)
b. Nil |
|
| + See chapter 19 for defined terms. | |
| | |
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix
3Y
Change
of Director’s Interest Notice
| No.
of securities held after change |
|
|
Shares |
Options |
|
| |
|
Direct |
3,752,817 |
23,179,148 |
|
| |
|
Indirect |
9,010,253 |
1,625,978 |
|
| |
|
Total |
12,763,070 |
24,805,126 |
| |
|
|
Nature
of change
Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend
reinvestment plan, participation in buy-back |
Acquisition
of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September
2026. |
Part
2 – Change of director’s interests in contracts
Note:
In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director”
should be disclosed in this part.
| Detail
of contract |
N/A |
| Nature
of interest |
N/A |
Name
of registered holder
(if
issued securities) |
N/A |
| Date
of change |
N/A |
No.
and class of securities to which interest related prior to change
Note:
Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest
acquired |
N/A |
| Interest
disposed |
N/A |
Value/Consideration
Note:
If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest
after change |
N/A |
| + See chapter 19 for defined terms. | |
| | |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix
3Y
Change
of Director’s Interest Notice
Part
3 – Closed period
| Were
the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? |
No |
| If
so, was prior written clearance provided to allow the trade to proceed during this period? |
N/A |
| If
prior written clearance was provided, on what date was this provided? |
N/A |
| + See chapter 19 for defined terms. | |
| | |
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix
3Y
Change
of Director’s Interest Notice
Rule
3.19A.2
Appendix
3Y
Change
of Director’s Interest Notice
Information
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property
and may be made public.
Introduced
30/9/2001. Amended 01/01/11
| Name
of Entity: |
Radiopharm
Theranostics Limited (ASX: RAD) |
| ABN: |
57
647 877 889 |
We
(the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section
205G of the Corporations Act.
| Name
of Director: |
Paul
Hopper |
| Date
of Last Notice: |
27
August 2026 |
Part
1 - Change of director’s relevant interests in securities
In
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note:
In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director”
should be disclosed in this part.
| Direct
or Indirect Interest |
Direct |
|
| |
|
|
Nature
of indirect interest
(including
registered holder)
Note:
Provide details of the circumstances giving rise to the relevant interest. |
N/A |
|
| |
|
|
| Date
of change |
17
September 2026 |
| |
|
|
|
|
|
| No.
of securities held prior to change |
|
|
Shares |
Options |
|
| |
|
Direct |
53,900,000 |
26,142,000 |
|
| |
|
Indirect |
93,821,428 |
9,017,518 |
|
| |
|
Total |
147,721,428 |
35,159,518
|
|
| |
|
|
|
|
|
| Class |
|
a. Fully
Paid Ordinary Shares |
|
|
| |
|
b.
Listed Options |
|
|
| Number
acquired |
|
Indirect |
|
|
| |
|
a. 2,777,778
Fully Paid Ordinary Shares |
|
| |
|
b. 2,777,778
Listed Options, EXP 31 Jul 29, EX $0.018 |
|
| |
|
|
|
| Number
disposed |
|
Nil |
|
|
|
| |
|
|
|
|
|
| Value/Consideration |
|
a. $25,000
($0.009 per Share) |
|
|
Note:
If consideration
is non-cash, provide details and estimated valuation |
|
b. Nil |
|
|
| + See chapter 19 for defined terms. | |
| | |
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix
3Y
Change
of Director’s Interest Notice
| No.
of securities held after change |
|
|
Shares |
Options |
|
| |
|
Direct |
53,900,000 |
26,142,000 |
|
| |
|
Indirect |
96,599,206 |
11,795,296 |
|
| |
|
Total |
150,499,206 |
37,937,296 |
| |
|
|
Nature
of change
Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend
reinvestment plan, participation in buy-back |
Acquisition
of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September
2026. |
Part
2 – Change of director’s interests in contracts
Note:
In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director”
should be disclosed in this part.
| Detail
of contract |
N/A |
| Nature
of interest |
N/A |
Name
of registered holder
(if
issued securities) |
N/A |
| Date
of change |
N/A |
No.
and class of securities to which interest related prior to change
Note:
Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest
acquired |
N/A |
| Interest
disposed |
N/A |
Value/Consideration
Note:
If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest
after change |
N/A |
| + See chapter 19 for defined terms. | |
| | |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix
3Y
Change
of Director’s Interest Notice
Part
3 – Closed period
| Were
the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? |
No |
| If
so, was prior written clearance provided to allow the trade to proceed during this period? |
N/A |
| If
prior written clearance was provided, on what date was this provided? |
N/A |
| + See chapter 19 for defined terms. | |
| | |
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix
3Y
Change
of Director’s Interest Notice
Rule
3.19A.2
Appendix
3Y
Change
of Director’s Interest Notice
Information
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property
and may be made public.
Introduced
30/9/2001. Amended 01/01/11
| Name
of Entity: |
Radiopharm
Theranostics Limited (ASX: RAD) |
| ABN: |
57
647 877 889 |
We
(the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section
205G of the Corporations Act.
| Name
of Director: |
Riccardo Canevari |
| Date
of Last Notice: |
27
August 2026 |
Part
1 - Change of director’s relevant interests in securities
In
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note:
In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director”
should be disclosed in this part.
| Direct
or Indirect Interest |
Direct |
|
| |
|
|
Nature
of indirect interest
(including
registered holder)
Note:
Provide details of the circumstances giving rise to the relevant interest. |
N/A |
|
| |
|
|
| Date
of change |
17
September 2026 |
| |
|
|
|
|
|
| No.
of securities held prior to change |
|
|
Shares |
Options |
|
| |
|
Direct |
20,029,986 |
183,412,299 |
|
| |
|
Indirect |
2,650,000 |
- |
|
| |
|
Total |
22,679,986 |
183,412,299 |
| |
|
|
|
|
|
| Class |
a. Fully
Paid Ordinary Shares |
|
| |
b. Listed
Options |
|
| |
|
|
| Number
acquired |
a.
3,888,889 Fully Paid Ordinary Shares |
|
|
b. 3,888,889 Listed Options, EXP 31 Jul 29, EX $0.018 |
|
| |
|
|
| Number
disposed |
Nil |
|
| |
|
|
|
|
|
Value/Consideration
Note:
If
consideration is non-cash, provide details and estimated valuation |
a. $35,000
($0.009 per Share)
b. Nil |
|
| + See chapter 19 for defined terms. | |
| | |
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix
3Y
Change
of Director’s Interest Notice
| No.
of securities held after change |
|
|
Shares |
Options |
|
| |
|
Direct |
23,918,875 |
187,301,188 |
|
| |
|
Indirect |
2,650,000 |
- |
|
| |
|
Total |
26,568,875 |
187,301,188 |
| |
|
|
Nature
of change
Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend
reinvestment plan, participation in buy-back |
Acquisition
of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September
2026 |
Part
2 – Change of director’s interests in contracts
Note:
In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director”
should be disclosed in this part.
| Detail
of contract |
N/A |
| Nature
of interest |
N/A |
Name
of registered holder
(if
issued securities) |
N/A |
| Date
of change |
N/A |
No.
and class of securities to which interest related prior to change
Note:
Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest
acquired |
N/A |
| Interest
disposed |
N/A |
Value/Consideration
Note:
If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest
after change |
N/A |
| + See chapter 19 for defined terms. | |
| | |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix
3Y
Change
of Director’s Interest Notice
Part
3 – Closed period
| Were
the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? |
No |
| If
so, was prior written clearance provided to allow the trade to proceed during this period? |
N/A |
| If
prior written clearance was provided, on what date was this provided? |
N/A |
| + See chapter 19 for defined terms. | |
| | |
| 01/01/2011 | Appendix 3Y Page 3 |
